Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Prabhu Rajagopalan"'
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
Grade 3 or 4 adverse events possibly related to refametinib or sorafenib, occurring in {greater than or equal to}2 patients in either cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6739762d5f3f88061cfa4f75b3d7bb26
https://doi.org/10.1158/1078-0432.22459308
https://doi.org/10.1158/1078-0432.22459308
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of BAY 86-9766, a selective, potent, orally available, small-molecule allosteric inhibitor of mitogen-activated protein kinase 1/2 in patients with advanced solid tumors.Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15dee10b1d3e60f3bddbcf748ba9c9fa
https://doi.org/10.1158/1078-0432.c.6521624
https://doi.org/10.1158/1078-0432.c.6521624
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
Overview of dose-limiting toxicities and adverse events leading to discontinuation and relationship to study treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258db69f0ab944ea9a5828a4ff6377c2
https://doi.org/10.1158/1078-0432.22459305
https://doi.org/10.1158/1078-0432.22459305
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
Refametinib geometric mean (% coefficient of variation) multiple-dose pharmacokinetic data on day 1 of course 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::543df570df003837b9fd1f2e8a53a365
https://doi.org/10.1158/1078-0432.22459299.v1
https://doi.org/10.1158/1078-0432.22459299.v1
Autor:
Martijn P. Lolkema, Ingmar Bruns, Jaap Verweij, Ron H.J. Mathijssen, Simon Langer, Isabelle Genvresse, Prabhu Rajagopalan, Kumar Sankhala, Martin Gutierrez, Joseph P. Eder, Patricia M. LoRusso, Anthony W. Tolcher, Sant P. Chawla, Jennifer R. Diamond, Vivek Subbiah, Oliver Boix, Florence Atrafi
Supplementary Table from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091d189809c695666a51560b3929acf1
https://doi.org/10.1158/1078-0432.22482266.v1
https://doi.org/10.1158/1078-0432.22482266.v1
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
Incidence of treatment-emergent adverse events, all grades, occurring in {greater than or equal to}20% of patients in either cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf1509851ce86e1c831f06bf4cb4c3c
https://doi.org/10.1158/1078-0432.22459311
https://doi.org/10.1158/1078-0432.22459311
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
CTC enumeration and pERK analysis in course 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9466f57cc4dc9356c8e18c20951a2d91
https://doi.org/10.1158/1078-0432.22459314
https://doi.org/10.1158/1078-0432.22459314
Autor:
Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Table S1: Dose-limiting toxicities; Table S2:Multiple-dose pharmacokinetic parameters (geometric mean (%CV) of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for once-daily dosing cohorts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645195f61f0c767c06b724819cf4f1ab
https://doi.org/10.1158/1078-0432.22449329.v1
https://doi.org/10.1158/1078-0432.22449329.v1
Autor:
Neil J. Clendeninn, Heiko Krissel, Prabhu Rajagopalan, Kimberly J. Manhard, David M. Wilson, Sonny Gunawan, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Diane P. Leffingwell, Lawrence Garbo, Morris Sherman, Aram F. Hezel, Joe J. Stephenson, Carlos H.R. Becerra, Fadi Braiteh, Anthony El-Khoueiry, Donald A. Richards, Alex A. Adjei
pERK levels in hair follicles by dose level and course
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd6316716f41142f3238c30b48b2bfe
https://doi.org/10.1158/1078-0432.22459317.v1
https://doi.org/10.1158/1078-0432.22459317.v1
Autor:
Martijn P. Lolkema, Ingmar Bruns, Jaap Verweij, Ron H.J. Mathijssen, Simon Langer, Isabelle Genvresse, Prabhu Rajagopalan, Kumar Sankhala, Martin Gutierrez, Joseph P. Eder, Patricia M. LoRusso, Anthony W. Tolcher, Sant P. Chawla, Jennifer R. Diamond, Vivek Subbiah, Oliver Boix, Florence Atrafi
Supplementary Figure from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045f71938a1d19f332e7f0706c610266
https://doi.org/10.1158/1078-0432.22482275.v1
https://doi.org/10.1158/1078-0432.22482275.v1